IKT Inhibikase Therapeutics Inc.
Drug Pipeline
| Drug | Stage | Notes |
|---|---|---|
|
IkT-148009
Parkinson’s disease
|
Phase 1
Phase 1
|
Phase 1 initiation of dosing announced February 17, 2021.
|
Latest News
-
View Full Article Hide Full Article
ATLANTA, May 17, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders inside and outside of the brain, today reported financial results for the first quarter ended March 31, 2021 and highlighted recent developments.
Key Business and Clinical Highlights
- Accelerated timelines for Phase 1 Study of IkT-148009 for the treatment of PD and associated GI Disorders: In February, 2021 Inhibikase commenced patient dosing in its Phase 1 study evaluating the safety, tolerability and pharmacokinetics of IkT-148009, the Company's novel brain penetrant Abelson tyrosine kinase (c-Abl) inhibitor with the potential to modify Parkinson's disease and its gastrointestinal complications. In April, 2021, the Company announced that it had accelerated the timeline for completion of the study based on early data that provided the opportunity to seek regulatory approval to commence dosing of PD patients in the third quarter of 2021, much earlier than previously anticipated.
- Advancing chronic toxicology studies of IkT-148009 to permit long-term dosing in patients: In January, 2021 Inhibikase initiated 3- and 6-month long-term toxicology studies of IkT-148009 in mice and 3- and 9-month long-term toxicology studies of IkT-148009 in primates as required to obtain regulatory approval for chronic administration of IkT-148009 in patients. The Company has completed 3-month toxicology studies and is presently completing its histopathology analysis in preparation for submission of the data for regulatory review early in the third quarter of 2021. The Company expects to complete 6- and 9-month toxicology studies in the fourth quarter of 2021.
- Initiated clinical batch manufacturing and pill formulation of IkT-001Pro. In February, 2021, Inhibikase initiated clinical batch manufacturing and final product formulation of IkT-001Pro, the Company's prodrug formulation of Imatinib, designed as a potentially safer, better tolerated treatment for Imatinib-sensitive cancers such as stable-phase Chronic Myeloid Leukemia (CML). Inhibikase expects to file an Investigational New Drug (IND) application in the third quarter of 2021, with initiation of clinical development as soon as practicable after the filing, subject to FDA acceptance of the IND.
"We are proud of the milestones we have achieved in the first quarter of 2021. The acceleration of our Phase 1 study for our lead candidate, IkT-148009 should allow us to move into evaluation of the safety, tolerability and pharmacokinetics in Parkinson's patients early in the third quarter of 2021. Concurrently, we are advancing two long term toxicology studies in animals, which will allow for chronic administration of IKT-148009 in patients following FDA review and acceptance," commented Milton Werner, Ph.D., President and Chief Executive Officer of Inhibikase. "In the third quarter of 2021, we plan to file our IND application for IKT-001Pro, which holds the potential to be a safer and better tolerated treatment for cancers such as CML, and expect to initiate clinical development as soon as practicable following the submission of the IND application. We look forward to making 2021 a success as we work to advance our early stage programs forward."
First Quarter Financial Review
Net Loss: Net loss for the quarter ended March 31, 2021, was $2.6 million, or $0.26 per share, compared to a net loss of $0.5 million, or $0.07 per share for the first quarter in 2020.
R&D Expenses: Research and development expenses were $2.4 million for the quarter ended March 31, 2021 compared to $0.3 million for the first quarter in 2020. The increase was driven by an increase in grant related research expenditures and non-grant related research. The non-grant related research was expended primarily in connection with the Company's Phase 1 clinical trials.
SG&A Expenses: Selling, general and administrative expenses for the quarter ended March 31, 2021 were $1.6 million compared to $0.5 million for the first quarter in 2020. The increase was primarily the result of increased non-cash stock compensation expense, increased directors and officer's liability insurance related to the Company's initial public offering in December 2020, increased legal fees, board fees, investor relations and consulting fees relating to operating as a public company registrant since December 2020, and an increase in other normal operating expenses.
Cash Position: Cash and cash equivalents were $9.6 million as of March 31, 2021.
About Inhibikase (www.inhibikase.com)
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders. Inhibikase's multi-therapeutic pipeline focuses on neurodegeneration and its lead program for IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, intends to treat Parkinson's disease inside and outside the brain. Inhibikase is currently performing its Phase I, randomized single ascending dose and multiple ascending dose, study to determine the safety, tolerability and pharmacokinetics of IkT-148009 in older and healthy subjects. The Company is also advancing a novel drug delivery platform to treat certain forms of cancer at the same time as it is developing novel drugs for the treatment of neurodegenerative disease. Inhibikase is headquartered in Atlanta, Georgia with offices in Boston, Massachusetts.Social Media Disclaimer
Investors and others should note that we announce material financial information to our investors using our investor relations website, press releases, SEC filings and public conference calls and webcasts. The company intends to also use Twitter, Facebook, LinkedIn and YouTube as a means of disclosing information about the company, its services and other matters and for complying with its disclosure obligations under Regulation FD.Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking terminology such as "believes," "expects," "may," "will," "should," "anticipates," "plans," or similar expressions or the negative of these terms and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on Inhibikase's current expectations and assumptions. Such statements are subject to certain risks and uncertainties, which could cause Inhibikase's actual results to differ materially from those anticipated by the forward-looking statements. One such uncertainty is that positive results from early clinical studies of our product candidates are not necessarily predictive of the results of later clinical studies and any current and future clinical trials of our product candidates. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth from time to time in Inhibikase's filings with the SEC, including its annual report on Form 10-K filed on March 31, 2021, including under the caption "Risk Factors." Any forward-looking statement in this release speaks only as of the date of this release. Inhibikase undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.Inhibikase Therapeutics, Inc.
Condensed Balance SheetsMarch 31,
2021
December 31,
2020
(unaudited)
Assets
Current assets:
Cash
$
9,609,631
$
13,953,513
Accounts receivable
332,774
—
Prepaid research and development
712,674
774,356
Prepaid expenses and other current assets
1,216,173
54,837
Total
11,871,252
14,782,706
Deferred offering costs
2,783
—
Total assets
$
11,874,035
$
14,782,706
Liabilities and stockholders' equity
Current liabilities:
Accounts payable
$
715,016
$
1,720,680
Accrued expenses and other current liabilities
627,399
632,934
Deferred revenue
1,251,349
2,325,741
Notes payable
994,789
42,534
Total
3,588,553
4,721,889
Notes payable, net of current portion
248,911
276,461
Total liabilities
3,837,464
4,998,350
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized at
March 31, 2021 and December 31, 2020; 0 shares issued and
outstanding at March 31, 2021 and December 31, 2020.—
—
Common stock, $0.001 par value; 100,000,000 and 30,000,000
shares authorized; 10,059,849 and 10,050,849 shares issued and
outstanding at March 31, 2021 and December 31, 2020, respectively.10,060
10,051
Additional paid-in capital
25,695,203
24,805,929
Accumulated deficit
(17,668,692)
(15,031,624)
Total
8,036,571
9,784,356
Total liabilities and stockholders' equity
$
11,874,035
$
14,782,706
Inhibikase Therapeutics, Inc.
Condensed Statements of Operations
(Unaudited)Three Months Ended March 31,
2021
2020
Revenue:
Grant revenue
$
1,407,165
$
270,787
Total revenue
1,407,165
270,787
Costs and expenses:
Research and development
2,431,860
283,114
Selling, general and administrative
1,600,576
527,688
Total costs and expenses
4,032,436
810,802
Loss from operations
(2,625,271)
(540,015)
Interest expense
(11,797)
(7,425)
Net loss
$
(2,637,068)
$
(547,440)
Net loss per share – basic and diluted
$
(0.26)
$
(0.07)
Weighted-average number of common shares – basic and diluted
10,053,949
8,181,734
View original content to download multimedia:http://www.prnewswire.com/news-releases/inhibikase-therapeutics-reports-first-quarter-2021-financial-results-and-highlights-recent-period-activity-301292776.htmlSOURCE Inhibikase Therapeutics, Inc.
-
View Full Article Hide Full Article
ATLANTA, April 21, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders inside and outside of the brain, today announced that Milton Werner, Ph.D., President and Chief Executive Officer, will provide an update on clinical measures of dosing pharmacokinetics and elaborate on IKT-148009's mechanism of action at the Sachs 4th Annual Neuroscience Innovation Forum being held virtually on April 28-30, 2021.
Dr. Werner will provide a corporate presentation, as well as participate in the Parkinson's & Movement Disorders panel discussion on Wednesday, April 28th, at 1:20 p.m. ET. In addition, Dr. Werner will separately present a corporate overview of Inhibikase.
About Inhibikase (www.inhibikase.com)
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders. Inhibikase's multi-therapeutic pipeline focuses on neurodegeneration and its lead program for IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, intends to treat Parkinson's disease inside and outside the brain. Inhibikase is currently performing its Phase I, randomized single ascending dose and multiple ascending dose, study to determine the safety, tolerability and pharmacokinetics of IkT-148009 in older and healthy subjects. The Company is also advancing a novel drug delivery platform to treat certain forms of cancer at the same time as it is developing novel drugs for the treatment of neurodegenerative disease. Inhibikase is headquartered in Atlanta, Georgia with offices in Boston, Massachusetts.
Social Media Disclaimer
Investors and others should note that we announce material financial information to our investors using our investor relations website, press releases, SEC filings and public conference calls and webcasts. The company intends to also use Twitter, Facebook, LinkedIn and YouTube as a means of disclosing information about the company, its services and other matters and for complying with its disclosure obligations under Regulation FD.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking terminology such as "believes," "expects," "may," "will," "should," "anticipates," "plans," or similar expressions or the negative of these terms and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on Inhibikase's current expectations and assumptions. Such statements are subject to certain risks and uncertainties, which could cause Inhibikase's actual results to differ materially from those anticipated by the forward-looking statements. One such uncertainty is that positive results from early clinical studies of our product candidates are not necessarily predictive of the results of later clinical studies and any current and future clinical trials of our product candidates. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth from time to time in Inhibikase's filings with the SEC, including its annual report on Form 10-K filed on March 31, 2021, including under the caption "Risk Factors." Any forward-looking statement in this release speaks only as of the date of this release. Inhibikase undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.
View original content to download multimedia:http://www.prnewswire.com/news-releases/inhibikase-therapeutics-to-present-at-sachs-4th-annual-neuroscience-innovation-forum-301273319.htmlSOURCE Inhibikase Therapeutics, Inc.
-
View Full Article Hide Full Article
ATLANTA, April 1, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease (PD) and related disorders inside and outside of the brain, today reported financial results for the fourth quarter and full year ended December 31, 2020 and highlighted recent developments.
Key Business and Clinical Highlights
- Completed Initial Public Offering: In December 2020, Inhibikase successfully completed its initial public offering (IPO) of 1,800,000 shares of common stock at a public offering price of $10.00 per share. The Company received aggregate net proceeds of approximately $14.60 million after deducting offering costs, underwriting discounts and commissions.
- Commenced Dosing of Patients in Phase 1 Study of IkT-148009 for the treatment of PD and associated GI Disorders: In February 2021, Inhibikase commenced patient dosing in older and elderly healthy volunteers in a Phase 1 randomized single ascending dose and multiple ascending dose study to determine the safety, tolerability and pharmacokinetics of IkT-148009. IkT-148009 is a novel brain penetrant Abelson tyrosine kinase, or c-Abl, inhibitor intended to be used to modify Parkinson's disease and its gastrointestinal complications.
- Accelerated timelines for completion of the Phase 1 trial and initiation of dosing in PD patients. Early data from this study have led to a reduction in the timelines for completion of the study by 6 or more months, providing the opportunity to obtain regulatory approval to commence dosing of PD patients much earlier than previously anticipated.
- Commenced chronic toxicology studies of IkT-148009 to permit long-term dosing in patients. In January, 2021 Inhibikase commenced 3 month and 6 month long-term toxicology studies of IkT-148009 in rats and 3 month and 9 month long-term toxicology studies of IkT-148009 in monkeys as required to obtain regulatory approval for chronic administration of IkT-148009 in patients. These studies are expected to be completed in the fourth quarter of 2021.
- Commenced clinical batch manufacturing and pill formulation of IkT-001Pro in preparation for an Investigational New Drug application filing in the second quarter of 2021. In February, 2021 Inhibikase commenced clinical batch manufacturing and final product formulation of IkT-001Pro as a film-coated tablet in preparation for regulatory filing with the Food and Drug Administration to initiate clinical development. This regulatory filing is anticipated to be completed near the end of the second quarter of 2021, with initiation of clinical development 30 days after the filing, subject to FDA agreement and issuance of a Study May Proceed notification.
"2020 was a transformative year for Inhibikase, as we successfully completed our IPO and worked diligently to advance our novel programs to treat neurodegenerative diseases towards the clinic," commented Milton Werner, Ph.D., President and Chief Executive Officer of Inhibikase. "Just recently, we were pleased to announce the advancement of our lead candidate, IkT-148009, into a Phase 1 dose escalation study to evaluate the safety, tolerability and pharmacokinetics in elderly volunteers. Early data from this study has been encouraging and we are shortening the timeline to completion by six or more months, with an expectation to move into early patient studies this year. We believe that IKT-148009 could be a transformative therapy for millions of Parkinson's patients worldwide. Simultaneously, we have advanced our oncology clinical candidate, IkT-001Pro, into manufacturing and expect to initiate clinical development early in the third quarter. Our highly dedicated team has exceeded all of our internal expectations to move these clinical programs forward for the benefit of patients."
Fourth Quarter and Full Year 2020 Financial Review
Net Loss: Net loss for the fourth quarter ended December 31, 2020, was $1.21 million, or $0.15 per share, compared to a net loss of $0.43 million, or $0.05 per share for the fourth quarter 2019. For the full year ended December 31, 2020, net loss was $2.85 million, or $0.35 per share, compared to a net loss of $5.72 million, or $0.70 per share, for the same period in 2019.
R&D Expenses: Research and development expenses were $0.23 million for the fourth quarter 2020, compared to $0.27 million for the same period in 2019. For the full year 2020, research and development expenses were $0.89 million, compared to $2.55 million for the same period in 2019. The decrease was primarily driven by a decline in grant related research expenditures and non-grant related research.
SG&A Expenses: Selling, general and administrative expenses for the fourth quarter 2020 were $1.14 million compared to $0.39 million for the fourth quarter 2019. For the full year 2020, selling, general and administrative expenses were $2.62 million, compared to $4.27 million for the same period in 2019. The decrease was primarily related to a non-recurring 2019 charge of $1.59 million of deferred IPO costs in connection with the 2018 abandoned IPO effort plus net decrease in all other selling, general and administrative expenses of $0.06 million.
Cash Position: Cash and cash equivalents were $13.95 million as of December 31, 2020.
About Inhibikase (www.inhibikase.com)
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders. Inhibikase's multi-therapeutic pipeline focuses on neurodegeneration and its lead program for IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, intends to treat Parkinson's disease inside and outside the brain. Inhibikase is currently performing its Phase I, randomized single ascending dose and multiple ascending dose, study to determine the safety, tolerability and pharmacokinetics of IkT-148009 in older and healthy subjects. The Company is also advancing a novel drug delivery platform to treat certain forms of cancer at the same time as it is developing novel drugs for the treatment of neurodegenerative disease. Inhibikase is headquartered in Atlanta, Georgia with offices in Boston, Massachusetts.Social Media Disclaimer
Investors and others should note that we announce material financial information to our investors using our investor relations website, press releases, SEC filings and public conference calls and webcasts. The company intends to also use Twitter, Facebook, LinkedIn and YouTube as a means of disclosing information about the company, its services and other matters and for complying with its disclosure obligations under Regulation FD.
The information we post through these social media channels may be deemed material. Accordingly, we encourage investors and others interested in our company to review the information we make available through these channels. in addition to following the company's press releases, SEC filings and public conference calls and webcasts. This list may be updated from time to time.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking terminology such as "believes," "expects," "may," "will," "should," "anticipates," "plans," or similar expressions or the negative of these terms and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on Inhibikase's current expectations and assumptions. Such statements are subject to certain risks and uncertainties, which could cause Inhibikase's actual results to differ materially from those anticipated by the forward-looking statements. One such uncertainty is that positive results from early clinical studies of our product candidates are not necessarily predictive of the results of later clinical studies and any current and future clinical trials of our product candidates. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth from time to time in Inhibikase's filings with the SEC, including its annual report on Form 10-K filed on March 31, 2021, including under the caption "Risk Factors." Any forward-looking statement in this release speaks only as of the date of this release. Inhibikase undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.Inhibikase Therapeutics, Inc.
Balance SheetsDecember 31,
2020
December 31,
2019
Assets
Current assets:
Cash
$
13,953,513
$
18,457
Prepaid research and development
774,356
—
Prepaid expenses and other current assets
54,837
16,924
Total
14,782,706
35,381
Deferred initial public offering costs
—
2,873
Total assets
$
14,782,706
$
38,254
Liabilities and stockholders' deficit
Current liabilities:
Accounts payable
$
1,720,680
$
1,001,699
Accrued expenses and other current liabilities
632,934
1,724,141
Deferred revenue
2,325,741
1,428,636
Notes payable
42,534
98,419
Total
4,721,889
4,252,895
Notes payable, net of current portion
276,461
275,375
Total liabilities
4,998,350
4,528,270
Commitments and contingencies
Stockholders' equity (deficit):
Preferred stock, $0.001 par value; 10,000,000 and 0 shares
authorized at December 31, 2020 and 2019; 0 shares issued and
outstanding at December 31, 2020 and 2019—
—
Common stock, $0.001 par value; 100,000,000 and 30,000,000
shares authorized; 10,050,849 and 8,180,937 shares
issued and outstanding at December 31, 2020 and 201910,051
8,181
Additional paid-in capital
24,805,929
7,685,533
Accumulated deficit
(15,031,624)
(12,183,730)
Total
9,784,356
(4,490,016)
Total liabilities and stockholders' equity (deficit)
$
14,782,706
$
38,254
Inhibikase Therapeutics, Inc.
Statements of OperationsYear ended December 31,
2020
2019
Revenue:
Grant revenue
$
698,468
$
1,122,740
Total revenue
698,468
1,122,740
Costs and expenses:
Research and development
893,802
2,552,711
Selling, general and administrative
2,623,158
4,268,177
Total costs and expenses
3,516,960
6,820,888
Loss from operations
(2,818,492)
(5,698,148)
Interest expense
(29,402)
(24,835)
Net loss
$
(2,847,894)
$
(5,722,983)
Net loss per share – basic and diluted
$
(0.35)
$
(0.70)
Weighted-average number of common shares – basic and diluted
8,212,581
8,180,937
Inhibikase Therapeutics, Inc.
Statements of OperationsQuarter ended December 31,
2020
2019
Revenue:
Grant revenue
$
170,416
$
240,276
Total revenue
170,416
240,276
Costs and expenses:
Research and development
226,944
267,915
Selling, general and administrative
1,144,319
394,624
Total costs and expenses
1,371,263
662,539
Loss from operations
(1,200,847)
(422,263)
Interest expense
(7,139)
(7,747)
Net loss
$
(1,207,986)
$
(430,010)
Net loss per share – basic and diluted
$
(0.15)
$
(0.05)
Weighted-average number of common shares – basic and diluted
8,286,886
8,180,937
View original content to download multimedia:http://www.prnewswire.com/news-releases/inhibikase-therapeutics-reports-fourth-quarter-and-full-year-2020-financial-results-and-highlights-recent-period-activity-301260390.htmlSOURCE Inhibikase Therapeutics, Inc.
- Completed Initial Public Offering: In December 2020, Inhibikase successfully completed its initial public offering (IPO) of 1,800,000 shares of common stock at a public offering price of $10.00 per share. The Company received aggregate net proceeds of approximately $14.60 million after deducting offering costs, underwriting discounts and commissions.
-
View Full Article Hide Full Article
ATLANTA, Mar. 2, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders inside and outside of the brain, today announced that Milton Werner, Ph.D., Chief Executive Officer of Inhibikase, will present at the H.C. Wainwright & Co. Global Life Sciences Virtual Conference.
The presentation will be available for on-demand viewing under "News & Events" in the Investors section of the Company's website at www.inhibikcase.com, beginning Tuesday, March 9th, 2021 at 7:00 am ET. The webcast will be available for approximately 90 days following the event.
About Inhibikase (www.inhibikase.com)
Inhibikase (NASDAQ:IKT) is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders. Inhibikase's multi-therapeutic pipeline focuses on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson's disease inside and outside the brain. Inhibikase is currently escalating dose in its Phase I, randomized single ascending dose and multiple ascending dose study to determine the safety, tolerability and pharmacokinetics of IkT-148009 in older and healthy subjects. Inhibikase is headquartered in Atlanta, Georgia with offices in Boston, Massachusetts.
View original content to download multimedia:http://www.prnewswire.com/news-releases/inhibikase-therapeutics-to-present-at-hc-wainwright--co-global-life-sciences-virtual-conference-301238073.htmlSOURCE Inhibikase Therapeutics, Inc.
-
View Full Article Hide Full Article
ATLANTA, Feb. 22, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders, today announced that it will present findings from its oral therapy studies for its lead agent IkT-148009 in progressive disease models of Parkinson's at the American Society of Experimental Neurotherapeutics (ASENT) 2021 Annual Meeting, being held virtually from February 22 - 25, 2021.
Inhibikase's President and Chief Executive Officer, Milton Werner, Ph.D. will describe the benefits observed following therapeutic, oral, daily administration of IkT-148009 in humanized mouse models of slowly progressive Parkinson's disease (PD). These outcomes suggest a mechanistic understanding of the role of alpha-synuclein plaques in the onset of disease.
Details for the presentation are below:
Event: American Society of Experimental Neurotherapeutics Conference
Session: Symposium on Parkinson's Disease: New Approaches
Presentation Title: Disease modification of Parkinson's Disease through oral kinase inhibitor therapy
Presentation Date: Thursday, February 25, 2021
Time: 10:20-10:40am ETFollowing the presentation, there will be a live panel discussion and Q&A session from 11:00-11:15am ET.
"We are excited to share some of the preclinical results of our IkT-148009 program at the ASENT 2021 conference. C-Abl is believed to be activated by the presence of alpha-synuclein plaque within affected neurons and subsequently, chemically modifies them, which we believe is a key event initiating the disease process in PD," stated Dr. Werner. "We believe that IkT-148009, may have the potential to alter the course of PD and transform the lives of millions of patients worldwide."
IkT-148009 is intended to be a once daily oral therapy to modify the progression of PD and has demonstrated functional recovery in animal models of Parkinson's disease in the brain and gastrointestinal, or GI, tract, two major organs affected by PD in humans. IkT-148009 is currently in Phase 1 clinical trials for the treatment of PD.
About Inhibikase (www.inhibikase.com)
Inhibikase (NASDAQ:IKT) is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders. Inhibikase's multi-therapeutic pipeline focuses on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson's disease inside and outside the brain. Inhibikase is currently dosing patients in its Phase I, randomized single ascending dose and multiple ascending dose in study to determine the safety, tolerability and pharmacokinetics of IkT-148009 in older and healthy subjects. Inhibikase is headquartered in Atlanta, Georgia with offices in Boston, Massachusetts.Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking terminology such as "believes," "expects," "may," "will," "should," "anticipates," "plans," or similar expressions or the negative of these terms and similar expressions are intended to identify forward-looking statements. These forward-looking statements, including statements regarding the closing of the initial public offering and the proceeds of the initial public offering, are based on Inhibikase's current expectations and assumptions. Such statements are subject to certain risks and uncertainties, which could cause Inhibikase's actual results to differ materially from those anticipated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in Inhibikase's filings with the SEC, including its registration statement on Form S-1, as amended (File No. 333-240036), including under the caption "Risk Factors." Any forward-looking statement in this release speaks only as of the date of this release. Inhibikase undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.Contacts:
Company Contact:
Milton H. Werner, PhD
President & CEO
678-392-3419
[email protected]Investor Relations:
Alex Lobo
SternIR, Inc.
[email protected]
View original content to download multimedia:http://www.prnewswire.com/news-releases/inhibikase-therapeutics-to-present-at-the-american-society-of-experimental-neurotherapeutics-asent-conference-301232095.htmlSOURCE Inhibikase Therapeutics, Inc.